<code id='4B6C75EE99'></code><style id='4B6C75EE99'></style>
    • <acronym id='4B6C75EE99'></acronym>
      <center id='4B6C75EE99'><center id='4B6C75EE99'><tfoot id='4B6C75EE99'></tfoot></center><abbr id='4B6C75EE99'><dir id='4B6C75EE99'><tfoot id='4B6C75EE99'></tfoot><noframes id='4B6C75EE99'>

    • <optgroup id='4B6C75EE99'><strike id='4B6C75EE99'><sup id='4B6C75EE99'></sup></strike><code id='4B6C75EE99'></code></optgroup>
        1. <b id='4B6C75EE99'><label id='4B6C75EE99'><select id='4B6C75EE99'><dt id='4B6C75EE99'><span id='4B6C75EE99'></span></dt></select></label></b><u id='4B6C75EE99'></u>
          <i id='4B6C75EE99'><strike id='4B6C75EE99'><tt id='4B6C75EE99'><pre id='4B6C75EE99'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:14
          Alnylam headquarters
          Kristoffer Tripplaar/Sipa USA/AP

          Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

          Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

          advertisement

          The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          California wildfire smoke linked to 52,000 early deaths, study says
          California wildfire smoke linked to 52,000 early deaths, study says

          DavidMcNew/GettyImagesWhenlargeswathsoftheEastCoastwereshroudedinwildfiresmokelastsummer,scientistsi

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          How faith leaders like me can help address America's obesity epidemic

          AdobeManyfactorsdriveAmerica’sobesityepidemic—environment,genetics,eatinghabits,andmore.Solvingthepr